Plain-English translation of NCT04741945 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication that has been used safely for decades to treat diabetes, might help prevent early blood disorders from turning into leukemia. Researchers believe this medication may slow or stop the progression of conditions called CCUS and low-risk MDS (myelodysplastic syndrome). The study will track how safe the medication is and whether it actually works to prevent cancer progression.
People with early blood disorders like CCUS and low-risk MDS face a real risk that their condition will eventually develop into leukemia, and there are currently no proven preventive treatments available. This medication has been studied in other cancers and may be able to slow the disease, offering hope to patients before their condition becomes more serious.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would take pills (up to 2,000 mg per day) for 12 months. You will have regular visits to check your blood work and how well you tolerate the medication. Researchers will also collect bone marrow samples and blood samples to understand how the medication is working and to compare your condition with healthy volunteers matched to your age and body type.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Denmark
Phase
Testing effectiveness
Sponsor
Kirsten Grønbæk
Collaborators
Steno Diabetes Center Copenhagen, Zealand University Hospital
Enrollment target
~40 participants
Started
December 2021
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kirsten Grønbæk, Professor, MD
Rigshospitalet, Denmark
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.